Information Provided By:
Fly News Breaks for May 9, 2018
HAE
May 9, 2018 | 08:39 EDT
Jefferies analyst Anthony Petrone raised his price target for Haemonetics to $95 saying the initial NexSys benefit is expected in Q2 with a larger ramp in the second half of the fiscal year. The analyst sees favorable terms and keeps a Buy rating on shares of Haemonetics.
News For HAE From the Last 2 Days
There are no results for your query HAE